Aardvark Therapeutics (NASDAQ:AARD) Stock Gets Price Target Reduction from HC Wainwright

Aardvark Therapeutics (NASDAQ:AARD) had its price target decreased by HC Wainwright from $6.00 to $4.00 in a report released on Monday,Benzinga reports. HC Wainwright currently has a neutral rating on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q3 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.69) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.74) EPS.

Other equities research analysts have also recently issued research reports about the company. BTIG Research restated a “neutral” rating on shares of Aardvark Therapeutics in a research note on Monday, October 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Thursday, September 24th. Finally, Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Aardvark Therapeutics presently has an average rating of “Hold” and a consensus price target of $11.89.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ:AARD opened at $4.41 on Monday. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $16.60. The stock has a market capitalization of $96.51 million, a price-to-earnings ratio of -1.37 and a beta of 3.80. The company has a 50-day simple moving average of $5.41 and a 200-day simple moving average of $5.30.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. As a group, research analysts forecast that Aardvark Therapeutics will post -3.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the transaction, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. The trade was a 63.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of large investors have recently modified their holdings of AARD. Susquehanna International Group LLP purchased a new stake in shares of Aardvark Therapeutics in the second quarter valued at approximately $138,000. J. Goldman & Co LP acquired a new position in Aardvark Therapeutics during the second quarter worth $233,000. Ieq Capital LLC acquired a new position in Aardvark Therapeutics during the second quarter worth $221,000. BlackRock Inc. purchased a new position in Aardvark Therapeutics in the second quarter worth $1,077,000. Finally, Renaissance Technologies LLC purchased a new position in Aardvark Therapeutics in the first quarter worth $267,000.

More Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: Zacks upgraded Aardvark Therapeutics to Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. The upgrade could support near-term investor interest. All You Need to Know About Aardvark Therapeutics Rating Upgrade to Buy
• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.69 from a projected loss of $3.80, while lifting its FY2027 estimate to a loss of $1.74 from $1.98. The firm also improved estimates for Q3 2026, Q4 2026, Q1 2027, Q2 2027 and Q3 2027, indicating expectations for reduced cash losses over much of the forecast period. HC Wainwright Estimates for Aardvark Therapeutics
• Neutral Sentiment: Despite the improved estimates, HC Wainwright maintained a Neutral rating and a $4.00 price target. That target indicates limited upside based on the firm’s valuation outlook and remains below the recent trading level cited in the company’s market data.
• Negative Sentiment: HC Wainwright reduced its Q4 2027 EPS estimate to a loss of $0.45 from $0.35, showing that the earnings outlook is not uniformly improving. Aardvark is still expected to report substantial losses, with consensus current-year EPS at negative $3.17.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.